All In Biotech

Drug Trial Radar · NCT07709910

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

382

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Nov 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.

Conditions

  • Participants With Obesity and Knee Osteoarthritis

Interventions

  • Ribupatide InjectionDrug

    Ribupatide Injection

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain score after 68 weeks of treatmentTime frame: after 68 weeks of continuous treatment, assessed every few weeks
  2. Percentage change from baseline in body weight after 68 weeks of treatmentTime frame: after 68 weeks of continuous treatment, assessed every few weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.